NIH R01 · 2024
A Divergent Platform to Chemically Redesign Bioactive 5-8-5 Terpenoids
PROJECT ABSTRACT Natural products continue to have a disproportionate impact on how we understand and treat disease. These biologically pre-validated therapeutic leads have inspired ~50% of FDA-approved drugs, a fact underscores the importance of studying biogenic chemotypes with unique activity in cell culture. Inspired by the rich opportunities for natural products at the interface of chemistry, biology, and medicine, this proposal focuses on a family of terpenoids distinguished by a fused [5-8-5] carbocyclic molecular framework. The flagship members of this family possess impactful, albeit divergent, pharmacological profiles. For example, fusicoccin A stabilizes 14-3-3 protein- protein…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.